Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.
Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T.
Tanioka M, et al. Among authors: yamada y, yamada k.
Cancer Chemother Pharmacol. 2011 Aug;68(2):505-11. doi: 10.1007/s00280-010-1506-7. Epub 2010 Nov 16.
Cancer Chemother Pharmacol. 2011.
PMID: 21079959
Clinical Trial.